Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion

2.

Kanter

J

,

Walters

MC

,

Krishnamurti

L

, et al.

Biologic and clinical efficacy of lentiglobin for sickle cell disease

.

N Engl J Med

.

2022

;

386

(

7

):

617

-

628

.

3.

Steinberg

MH

. Other sickle hemoglobinopathies. In:

Steinberg

MH

,

Forget

BG

,

Higgs

DR

,

Weatherall

DJ

, eds.

Disorders of hemoglobin: Genetics, Pathophysiology, and Clinical Management

. (10th ed) .

Cambridge University Press

;

2009

.

4.

Torres

LS

,

Okumura

JV

,

Belini-Júnior

É

, et al.

Phenotypic diversity of sickle cell disease in patients with a double heterozygosity for Hb S and HbD-Punjab

.

Hemoglobin

.

2016

;

40

(

5

):

356

-

358

.

5.

Milner

PF

,

Miller

C

,

Grey

R

,

Seakins

M

,

DeJong

WW

,

Went

LN

.

Hemoglobin O Arab in four negro families and its interaction with hemoglobin S and hemoglobin C

.

N Engl J Med

.

1970

;

283

(

26

):

1417

-

1425

.

6.

Goode

E

,

Boruchov

D

,

Oliveira

JL

,

Lau

CC

.

Hemoglobin S/Hemoglobin Quebec-Chori presenting as sickle cell disease: a case report

.

J Pediatr Hematol Oncol

.

2020

;

42

(

8

):

e775

-

e777

.

7.

Venugopal

S

,

Shaju

A

,

Dhuri

S

,

Al-Harthy

T

,

Jabal

KB

.

Compound heterozygosity for Hb S and Hb S-Oman: case report

.

Sultan Qaboos Univ Med J

.

2008

;

8

(

3

):

344

-

346

.

8.

Luo

H

,

Adewoye

AH

,

Eung

SH

, et al.

A novel sickle hemoglobin: hemoglobin S-South end

.

J Pediatr Hematol Oncol

.

2004

;

26

(

11

):

773

-

776

.

9.

Moo-Penn

W

,

Bechtel

K

,

Jue

D

, et al.

The presence of hemoglobin S and C Harlem in an individual in the United States

.

Blood

.

1975

;

46

(

3

):

363

-

367

.

10.

Monplaisir

N

,

Merault

G

,

Poyart

C

, et al.

Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes

.

Proc Natl Acad Sci U S A

.

1986

;

83

(

24

):

9363

-

9367

.

11.

Geva

A

,

Clark

JJ

,

Zhang

Y

,

Popowicz

A

,

Manning

JM

,

Neufeld

EJ

.

Hemoglobin Jamaica plain-a sickling hemoglobin with reduced oxygen affinity

.

N Engl J Med

.

2004

;

351

(

15

):

1532

-

1538

.

12.

Goosens

M

,

Garel

MC

,

Auvinet

J

, et al.

Hemoglobin C Ziguinchor α₂^Aβ₂⁶ (A3) glu->val β⁵⁸ (E2) pro->arg: the second sickling variant with amino acid substitutions in 2 residues of the β polypeptide chain

.

FEBS Let

.

1975

;

58

:

149

-

154

.

13.

Ducrocq

R

,

Dratkowski

P

,

Ithier

G

, et al.

A new major sickle cell syndrome: HbS (β6Val)/HbC Ndjamena (β6Val-β37Gly)

.

Hemoglobin

.

2006

;

30

:

33

-

41

.

14.

Préhu

C

,

Riou

J

,

Sartelet

I

, et al.

Hb O-Tibesti [beta121(GH4)Glu->Lys; beta11(A8)Val->Ile], a hemoglobin variant carrying in the same beta chain the substitutions of Hb O-Arab and Hb Hamilton, found in combination with Hb S [beta6(A3)Glu-->Val]

.

Hemoglobin

.

2002

;

26

(

1

):

13

-

20

.

15.

Paradisi

I

,

González

N

,

Hernández

A

,

Arias

S

.

Hemoglobin S/hemoglobin City of Hope compound heterozygote with a Sub Saharan genetic background and severe bone marrow hypoplasia

.

Invest Clin

.

2010

;

51

(

3

):

403

-

414

.

16.

Kutlar

F

,

Redding-Lallinger

R

,

Meiler

SE

,

Bakanay

SM

,

Borders

L

,

Kutlar

A

.

A new sickling variant 'Hb S-Wake β[(Glu6Val-Asn139 Ser)]' found in a compound heterozygote with Hb S β(Glu6Val) coinherited with homozygous α-thalassemia-2: phenotype and molecular characteristics

.

Acta Haematol

.

2010

;

124

(

2

):

120

-

124

.

17.

Masiello

D

,

Heeney

MM

,

Adewoye

AH

, et al.

Hemoglobin SE disease: a concise review

.

Am J Hematol

.

2007

;

82

(

7

):

643

-

649

.

18.

Lawrence

C

,

Hirsch

RE

,

Fataliev

NA

,

Patel

S

,

Fabry

ME

,

Nagel

RL

.

Molecular interactions between Hb alpha-G Philadelphia, HbC, and HbS: phenotypic implications for SC alpha-G Philadelphia disease

.

Blood

.

1997

;

90

(

7

):

2819

-

2825

.

19.

Gu

L-H

,

Wilson

JB

,

Molchanova

TP

,

McKie

KM

,

McKie

VC

,

Huisman

TH

.

Three sickle cell anemia patients each with a different alpha chain variant. Diagnostic complications

.

Hemoglobin

.

1993

;

17

(

4

):

295

-

301

.

20.

Seward

DP

,

Ware

RE

,

Kinney

TR

.

Hemoglobin sickle-Lepore: report of two siblings and review of the literature

.

Am J Hematol

.

1993

;

44

(

3

):

192

-

195

.

21.

Ahmed

SG

,

Ibrahim

UA

.

Non-S sickling hemoglobin variants: historical genetic diagnostic and clinical perspectives

.

Oman Med J

.

2021

;

36

(

3

):

e261

.

22.

Minniti

C

,

Brugnara

C

,

Steinberg

MH

.

HbSC disease: a time for progress

.

Am J Hematol

.

2022

;

97

(

11

):

1390

-

1393

.

23.

Motulsky

AG

.

Frequency of sickle disorders in US blacks

.

N Engl J Med

.

1973

;

288

(

1

):

31

-

33

.

24.

Piel

FB

,

Howes

RE

,

Patil

AP

, et al.

The distribution of haemoglobin C and its prevalence in newborns in Africa

.

Sci Rep

.

2013

;

3

:

1671

.

25.

Taylor

JG

,

Ackah

D

,

Cobb

C

, et al.

Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease

.

Am J Hematol

.

2008

;

83

(

1

):

6

-

14

.

26.

Steinberg

MH

,

Nagel

RL

. HbSC disease and hemoglobin C disorders other sickle hemoglobinopathies. In:

Steinberg

MH

,

Forget

BG

,

Higgs

DR

,

Weatherall

DJ

, eds.

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management

. (2nd ed) .

2009

.

27.

Platt

OS

,

Brambilla

DJ

,

Rosse

WF

, et al.

Mortality in sickle-cell disease. Life expectancy and risk-factors for early death

.

N Engl J Med

.

1994

;

330

(

23

):

1639

-

1644

.

28.

Platt

OS

,

Thorington

BD

,

Brambilla

DJ

, et al.

Pain in sickle cell disease. Rates and risk-factors

.

N Engl J Med

.

1991

;

325

(

1

):

11

-

16

.

29.

Lionnet

F

,

Hammoudi

N

,

Stojanovic

K

, et al.

Hemoglobin sickle cell disease complications: a clinical study of 179 cases

.

Haematol

.

2012

;

97

(

8

):

1136

-

1141

.

30.

Brewin

JN

,

Nardo-Marino

A

,

Stuart-Smith

S

, et al.

The pleiotropic effects of alpha thalassemia on HbSS and HbSC sickle cell disease: reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival

.

Am J Hematol

.

2022

;

97

(

10

):

1275

-

1285

.

31.

Dei-Adomakoh

YA

,

Segbefia

CI

,

Latham

TS

, et al.

Hydroxyurea for children and adults with hemoglobin SC disease

.

NEJM Evid

.

2025

;

4

(

2

):

EVIDoa2400402

.

32.

Steinberg

MH

,

Embury

SH

.

Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene

.

Blood

.

1986

;

68

(

5

):

985

-

990

.

33.

Shartava

A

,

Monteiro

CA

,

Bencsath

FA

, et al.

A posttranslational modification of beta-actin contributes to the slow dissociation of the spectrin-protein 4.1-actin complex of irreversibly sickled cells

.

J Cell Biol

.

1995

;

128

(

5

):

805

-

818

.

34.

Goodman

SR

.

The irreversibly sickled cell: a perspective

.

Cell Mol Biol

.

2004

;

50

(

1

):

53

-

58

.

35.

Franco

RS

,

Puchulu-Campanella

ME

,

Barber

LA

, et al.

Changes in the properties of normal human red blood cells during in vivo aging

.

Am J Hematol

.

2013

;

88

(

1

):

44

-

51

.

36.

Reese

TJ

,

Worth

EH

,

Fugate

MK

,

Levitt

MT

,

Ferrone

FA

.

Novel single-cell measurements suggest irreversibly sickled cells are neither dense nor dehydrated

.

Biophys J

.

2024

;

123

(

21

):

3750

-

3758

.

37.

Steinberg

MH

,

Nagel

RL

. HbSC disease and HbC disorders. In:

Steinberg

MH

,

Forget

BG

,

Higgs

DR

,

Weatherall

DJ

, eds.

Disorders of hemoglobin: Genetics, Pathophysiology, and Clinical Management

. (2nd ed) .

2009

.

38.

Nagel

RL

,

Fabry

ME

,

Steinberg

MH

.

The paradox of hemoglobin SC disease

.

Blood Rev

.

2003

;

17

(

3

):

167

-

178

.

39.

Eaton

WA

.

Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease

.

Mol Aspects Med

.

2022

;

84

:

100971

.

40.

Hirsch

RE

,

Samuel

RE

,

Fataliev

NA

, et al.

Differential pathways in oxy and deoxy HbC aggregation/crystallization

.

Proteins

.

2001

;

42

(

1

):

99

-

107

.

41.

Hirsch

RE

,

Raventos-Suarez

C

,

Olson

JA

,

Nagel

RL

.

Ligand state of intraerythrocytic circulating HbC crystals in homozygous CC patients

.

Blood

.

1985

;

66

(

4

):

775

-

777

.

42.

Hirsch

RE

,

Lin

MJ

,

Nagel

RL

.

The inhibition of hemoglobin C crystallization by hemoglobin F

.

J Biol Chem

.

1988

;

263

(

12

):

5936

-

5939

.

43.

Lin

MJ

,

Nagel

RL

,

Hirsch

RE

.

Acceleration of hemoglobin C crystallization by hemoglobin S

.

Blood

.

1989

;

74

(

5

):

1823

-

1825

.

44.

Gluckman

E

,

Cappelli

B

,

Bernaudin

F

, et al.

Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation

.

Blood

.

2017

;

129

(

11

):

1548

-

1556

.

45.

Rostami

T

,

Rad

S

,

Rostami

MR

, et al.

Hematopoietic stem cell transplantation in sickle cell disease: a multidimensional review

.

Cell Transpl

.

2024

;

33

:

9636897241246351

.

46.

Hsieh

MM

,

Kang

EM

,

Fitzhugh

CD

, et al.

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease

.

N Engl J Med

.

2009

;

361

(

24

):

2309

-

2317

.

47.

Shenoy

S

,

Eapen

M

,

Panepinto

JA

, et al.

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

.

Blood

.

2016

;

128

(

21

):

2561

-

2567

.

48.

Kassim

AA

,

de la Fuente

J

,

Nur

E

, et al.

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

.

Blood

.

2024

;

143

(

25

):

2654

-

2665

.

49.

Kassim

AA

,

Walters

MC

,

Eapen

M

, et al.

Haploidentical bone marrow transplantation for sickle cell disease

.

NEJM Evid

.

2025

;

4

(

3

):

EVIDoa2400192

.

50.

Nakamae

H

.

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation

.

Front Immunol

.

2024

;

15

:

1403936

.

51.

Miller

MK

,

Zimmerman

SA

,

Schultz

WH

,

Ware

RE

.

Hydroxyurea therapy for pediatric patients with hemoglobin SC disease

.

J Pediatr Hematol Oncol

.

2001

;

23

(

5

):

306

-

308

.

52.

Steinberg

MH

,

Nagel

RL

,

Brugnara

C

.

Cellular effects of hydroxyurea in Hb SC disease

.

Br J Haematol

.

1997

;

98

(

4

):

838

-

844

.

53.

Yates

AM

,

Dedeken

L

,

Smeltzer

MP

,

Lebensburger

JD

,

Wang

WC

,

Robitaille

N

.

Hydroxyurea treatment of children with hemoglobin SC disease

.

Pediatr Blood Cancer

.

2013

;

60

(

2

):

323

-

325

.

54.

Luchtman-Jones

L

,

Pressel

S

,

Hilliard

L

, et al.

Effects of hydroxyurea treatment for patients with hemoglobin SC disease

.

Am J Hematol

.

2016

;

91

(

2

):

238

-

242

.

55.

Wang

W

,

Brugnara

C

,

Snyder

C

, et al.

The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial

.

Br J Haematol

.

2011

;

152

(

6

):

771

-

776

.

56.

Powars

DR

,

Hiti

A

,

Ramicone

E

,

Johnson

C

,

Chan

L

.

Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors

.

Am J Hematol

.

2002

;

70

(

3

):

206

-

215

.

57.

Setayesh

T

,

Chi

M

,

Oestreicher

Z

, et al.

A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea

.

Blood

.

2025

;

146

(

1

):

13

-

28

.

58.

Porcu

S

,

Simbula

M

,

Marongiu

MF

, et al.

Delta-globin gene expression improves sickle cell disease in a humanised mouse model

.

Br J Haematol

.

2021

;

193

(

6

):

1228

-

1237

.

59.

Eaton

WA

,

Bunn

HF

.

Treating sickle cell disease by targeting HbS polymerization

.

Blood

.

2017

;

129

(

20

):

2719

-

2726

.

60.

Yang

E

,

Voelkel

EB

,

Lezon-Geyda

K

,

Schulz

VP

,

Gallagher

PG

.

Hemoglobin C trait accentuates erythrocyte dehydration in hereditary xerocytosis

.

Pediatr Blood Cancer

.

2017

;

64

(

8

):

e26444

.

61.

Gallagher

PG

.

Disorders of erythrocyte hydration

.

Blood

.

2017

;

130

(

25

):

2699

-

2708

.

62.

Hinchliffe

RF

,

Norcliffe

D

,

Farrar

LM

,

Lilleyman

JS

.

Mean cell haemoglobin concentration in subjects with haemoglobin C, D, E and S traits

.

Clin Lab Haematol

.

1996

;

18

(

4

):

245

-

248

.

63.

Bunn

HF

.

Subunit dissociation of certain abnormal human hemoglobins

.

J Clin Invest

.

1969

;

48

(

1

):

126

-

138

.

64.

Park

CM

.

The dimerization of deoxyhemoglobin and of oxyhemoglobin. Evidence for cleavage along the same plane

.

J Biol Chem

.

1970

;

245

(

20

):

5390

-

5394

.

65.

Bunn

HF

,

McDonough

M

.

Asymmetrical hemoglobin hybrids. An approach to the study of subunit interactions

.

Biochemistry

.

1974

;

13

(

5

):

988

-

993

.

66.

Gupta

AO

,

Sharma

A

,

Dalal

J

, et al. Base editing for sickle cell disease: ongoing results from the BEACON study evaluating the safety and efficacy of BEAM-101, the first base-edited autologous CD34+ HSPC one-time cell therapy. Paper presented at: European Hematology Association (EHA) 2025 Congress.

13 June 2025

. Milan, Italy.

67.

Steinberg

MH

.

Fetal hemoglobin in beta hemoglobinopathies: is enough too much?

.

Am J Hematol

.

2022

;

97

(

6

):

676

-

678

.

68.

Li

C

,

Georgakopoulou

A

,

Newby

GA

, et al.

In vivo HSC prime editing rescues sickle cell disease in a mouse model

.

Blood

.

2023

;

141

(

17

):

2085

-

2099

.

69.

Breda

L

,

Papp

TE

,

Triebwasser

MP

, et al.

In vivo hematopoietic stem cell modification by mRNA delivery

.

Science

.

2023

;

381

(

6656

):

436

-

443

.

70.

Frangoul

H

,

Stults

A

,

Bruce

K

, et al.

Best practices in gene therapy for sickle cell disease and transfusion-dependent β-thalassemia

.

Transpl Cell Ther

.

2025

;

31

(

6

):

352.e1

-

352.e10

.

71.

Fitzhugh

CD

,

Hsieh

MM

,

Bolan

CD

,

Saenz

C

,

Tisdale

JF

.

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

.

Cytotherapy

.

2009

;

11

(

4

):

464

-

471

.

72.

Steinberg

MH

.

Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes

.

J Clin Med

.

2020

;

9

(

11

):

3782

.

73.

Steinberg

MH

,

Kutlar

A

,

Sebastiani

P

,

Sebastiani

P

.

Mean corpuscular hemoglobin modulates HbF/F-cell and clinical response to gene therapy and hydroxyurea in sickle cell disease

.

Am J Hematol

.

2025

;

100

(

9

):

1647

-

1650

.